However, despite its benefit in patients with FLT3-ITD+ R/R AML, quizartinib is not clinically active against FLT3-TKD mutations, which develop as a consequence of FLT3 inhibitor therapy (12). This evidence concerns the gene FLT3 and acute myeloid leukemia.